MethylGene to Present at the Piper Jaffray 24th Annual Healthcare Conference
November 21 2012 - 12:00PM
Marketwired
MethylGene Inc. (TSX:MYG) today announced that Dr. Charles M. Baum,
President and Chief Executive Officer, will speak at the Piper
Jaffray 24th Annual Healthcare Conference. Dr. Baum's session is
scheduled for Wednesday November 28, 2012 at 2:30 p.m. EST at the
New York Palace hotel, New York, NY.
About MethylGene
MethylGene Inc. (TSX:MYG) is a drug development company that is
advancing novel therapeutics for cancer and infectious disease in
human clinical trials. The Company's lead product candidates are:
MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme
that is in Phase II trials for vulvovaginal candidiasis, and
MGCD265, a multi-targeted receptor tyrosine kinase inhibitor that
is in Phase I/II clinical trials for patients with solid tumors.
MethylGene owns all rights to its lead product candidates, and has
partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho
Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its
other pipeline programs.
Certain statements contained in this news release, other than
statements of fact that are independently verifiable at the date
hereof, may constitute forward-looking statement. Such statements,
based as they are on the current expectations of management of
MethylGene, inherently involve numerous risks and uncertainties,
known and unknown, many of which are beyond MethylGene's control.
These risks and uncertainties could cause future results,
performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Such results, performance or
achievements include, but are not limited to, the timing and
effects of regulatory action; the continuation of collaborations;
the results of clinical trials; the timing of enrollment or
completion of clinical trials; the success, efficacy or safety of
MGCD265, MGCD290 or our other programs; the ability to scale up,
formulate and manufacture sufficient GMP, clinical or
commercialization quantities of MGCD265, MGCD290 or our other
products, and the relative success or the lack of success in
developing and gaining regulatory approval and/or market acceptance
for any compound or new product including MGCD265 or MGCD290. Such
risks include, but are not limited to, the impact of general
economic conditions, economic conditions in the pharmaceutical
industry, changes in the regulatory environment in the
jurisdictions in which MethylGene does business, stock market
volatility, fluctuations in costs, expectations with respect to our
intellectual property position and our ability to protect our
intellectual property and operate our business without infringing
upon the intellectual property rights of others, changes in the
competitive landscape including changes in the standard of care for
the various indications in which MethylGene is involved, and
changes to the competitive environment due to consolidation, as
well as other risks, as described in MethylGene's Annual
Information Form under the heading "Risk Factors" which you are
urged to read, and all other documents filed by the Company that
can be found at www.sedar.com. Consequently, actual future results
may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue
reliance on the forward-looking statements included in this news
release. These statements speak only as of the date they are made
and MethylGene expressly disclaims any duty, obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in MethylGene's expectations with regard thereto of any change in
events, conditions or circumstances on which any such statements
are based except in accordance with law.
Contacts: Joseph Walewicz, CFA Vice President, Business &
Corporate Development MethylGene Inc. 514-337-3333 ext.
373ir@methylgene.com www.methylgene.com Thomas Hoffmann Vice
President The Trout Group LLC 646-378-2931thoffmann@troutgroup.com
www.troutgroup.com